Oxotremorine sesquifumarate | CAS# 17360-35-9 | Muscarinic agonist

MedKoo Cat#: 574381 | Name: Oxotremorine sesquifumarate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxotremorine sesquifumarate is a muscarinic agonist. Oxotremorine sesquifumarate diminished both the baseline, and K(+) triggered release of [(3)H]GABA from thalamic slices.

Chemical Structure

Oxotremorine sesquifumarate

CAS#17360-35-9

Theoretical Analysis

MedKoo Cat#: 574381

Name: Oxotremorine sesquifumarate

CAS#: 17360-35-9

Chemical Formula: C36H48N4O14

Exact Mass: 760.3167

Molecular Weight: 760.79

Elemental Analysis: C, 56.83; H, 6.36; N, 7.36; O, 29.44

Price and Availability

Size	Price	Availability
250mg	USD 435.00	2 Weeks
500mg	USD 635.00	2 Weeks
1g	USD 905.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Oxotremorine sesquifumarate

IUPAC/Chemical Name

1-(4-(pyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidin-2-one sesquifumarate

InChi Key

WLYYOFJEBGHKEC-VQYXCCSOSA-N

InChi Code

InChI=1S/2C12H18N2O.3C4H4O4/c2*15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13;3*5-3(6)1-2-4(7)8/h2*1-2,5-11H2;3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+

SMILES Code

OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.O=C1CCCN1CC#CCN1CCCC1.O=C1CCCN1CC#CCN1CCCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Oxotremorine sesquifumarate is a mAChR agonist that mainly activates M2 receptors.

In vitro activity:

Oxotremorine (10.5 micron) produced a paralytic effect on twitch responses of rat diaphragm in vitro to direct and indirect stimulation. The paralytic effect of oxotremorine was absent when the diaphragm was stimulated directly in the presence of hemicholinium-3 (0.42 mM), at a time when twitch responses to indirect stimulation ceased completely. Oxotremorine, at two different pharmacologically active doses, strikingly increased the resting as well as electrically evoked release of acetylcholine into the bathing fluid from the phrenic nerve-diaphragm preparation. Reference: Br J Pharmacol. 1978 Feb;62(2):195-8. https://pubmed.ncbi.nlm.nih.gov/203356/

In vivo activity:

The present study was performed to examine whether cold hypersensitivity and heat hyperalgesia in rats with partial sciatic nerve injuries can be attenuated by SCS in the same way as tactile hypersensitivity and to explore a possibly synergistic effect of SCS and a muscarinic receptor agonist, oxotremorine. Oxotremorine was administered intrathecally. Tactile, cold and heat sensitivities were assessed by using von Frey filaments, cold spray and focused radiant heat, respectively. Oxotremorine i.t. dose-dependently suppressed the tactile hypersensitivity. Reference: Neurosci Lett. 2008 May 2;436(1):7-12. https://pubmed.ncbi.nlm.nih.gov/18343581/

	Solvent	mg/mL	mM
Solubility
	DMF	16.0	21.03
	DMSO	59.0	77.57
	Ethanol	10.0	26.29
	PBS (pH 7.2)	3.0	3.94
	Water	54.8	71.97

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 760.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kim EC, Toyono T, Berlinicke CA, Zack DJ, Jurkunas U, Usui T, Jun AS. Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress. Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):892-900. doi: 10.1167/iovs.16-20147. PMID: 28159976; PMCID: PMC5295784. 2. Das M, Ganguly DK, Vedasiromoni JR. Enhancement by oxotremorine of acetylcholine release from the rat phrenic nerve. Br J Pharmacol. 1978 Feb;62(2):195-8. doi: 10.1111/j.1476-5381.1978.tb08445.x. PMID: 203356; PMCID: PMC1667799. 3. Frinchi M, Nuzzo D, Scaduto P, Di Carlo M, Massenti MF, Belluardo N, Mudò G. Anti-inflammatory and antioxidant effects of muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus. Sci Rep. 2019 Oct 2;9(1):14233. doi: 10.1038/s41598-019-50708-w. PMID: 31578381; PMCID: PMC6775129. 4. Song Z, Meyerson BA, Linderoth B. Muscarinic receptor activation potentiates the effect of spinal cord stimulation on pain-related behavior in rats with mononeuropathy. Neurosci Lett. 2008 May 2;436(1):7-12. doi: 10.1016/j.neulet.2008.02.044. Epub 2008 Feb 26. PMID: 18343581.

In vitro protocol:

In vivo protocol:

1. Frinchi M, Nuzzo D, Scaduto P, Di Carlo M, Massenti MF, Belluardo N, Mudò G. Anti-inflammatory and antioxidant effects of muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus. Sci Rep. 2019 Oct 2;9(1):14233. doi: 10.1038/s41598-019-50708-w. PMID: 31578381; PMCID: PMC6775129. 2. Song Z, Meyerson BA, Linderoth B. Muscarinic receptor activation potentiates the effect of spinal cord stimulation on pain-related behavior in rats with mononeuropathy. Neurosci Lett. 2008 May 2;436(1):7-12. doi: 10.1016/j.neulet.2008.02.044. Epub 2008 Feb 26. PMID: 18343581.

1. Fisher et al (1984) Differential stimulation in inositol phospholipid turnover in brain by analogs of oxotremorine. J.Neurochem. 43 1171 PMID: 6088696 2. Moroi-Fetters et al (1988) Muscarinic receptor-mediated phosphoinositide hydrolysis in the rat retina. J.Pharmacol.Exp.Ther. 246 553 PMID: 2841451 3: Rowell PP, Volk KA, Li J, Bickford ME. Investigations of the cholinergic modulation of GABA release in rat thalamus slices. Neuroscience. 2003;116(2):447-53. doi: 10.1016/s0306-4522(02)00706-6. PMID: 12559099. 4: Brioni JD, Izquierdo I. Retention enhancement by pre-test beta-endorphin and oxotremorine and its reversal by scopolamine. Behav Neural Biol. 1988 Nov;50(3):251-4. doi: 10.1016/s0163-1047(88)90922-3. PMID: 2849408.